Skip to main content
Premium Trial:

Request an Annual Quote

General Biologicals CellBio FX10, CellBio a2000, and RealQuant AIO

General Biologicals, a Taiwanese in vitro diagnostics manufacturer, has unveiled two CellBio circulating tumor cell (CTC) cancer detection products at the Association for Diagnostics and Laboratory Medicine (formerly the American Association for Clinical Chemistry) annual meeting. The two systems, the CellBio FX10 and CellBio a2000 both use GBC's proprietary iFiltration technology. Among claimed advantages, the firm cites detection from 7.5-mL blood samples with high specificity, sensitivity, and cancer capture rate, with a 90-minute turnaround time. The CellBio FX10 can work with 10 samples at a time with a full-color touch screen, while CellBio a2000 can detect two samples at a time in small-space labs. 

In addition to CTC systems, GBC also introduced its sample-to-results automated system, GB RealQuant AIO. The system consolidates extraction, amplification, and detection in one integrated instrument, providing results within two hours, and works with all GB RealQuant HBV, HCV, and HPV Kits.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.